Efficacy and safety of peg-IFN+RBV combined therapy in failure of direct antiviral agents therapy for chronic hepatitis C and liver cirrhosis C

Efficacy and safety of peg-IFN+RBV combined therapy in failure of direct antiviral agents therapy for chronic hepatitis C and liver cirrhosis C - Efficacy and safety of peg-IFN+RBV combined therapy in failure of direct antiviral agents therapy for chronic hepatitis C and liver cirrhosis C

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017988

Enrollment

Registered

2015-06-20

Start date

2015-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis and compensated liver cirrhosis, type C

Interventions

PegIFN plus RBV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: good informed patients

Exclusion criteria

Exclusion criteria: un-tolerable for combined therapy de compensated liver cirrhosis

Design outcomes

Primary

Measure	Time frame
sustained virological response	—

Countries

Japan

Contacts

Public ContactShinji Shimoda Shinji Shimoda

Faculty of Medicine, Kyushu University Dept. of Medicine and Biosystemic Science

sshimoda@intmed1.med.kyushu-u.ac.jp092-642-5231

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026